urinary ifabp concentrations Search Results


urinary ifabp concentrations  (R&D Systems)
94
R&D Systems urinary ifabp concentrations
Baseline anthropometry, faecal calprotectin concentrations and urinary and plasma concentrations of <t> iFABP </t>
Urinary Ifabp Concentrations, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/urinary ifabp concentrations/product/R&D Systems
Average 94 stars, based on 1 article reviews
urinary ifabp concentrations - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

Image Search Results


Baseline anthropometry, faecal calprotectin concentrations and urinary and plasma concentrations of iFABP

Journal: BMC Gastroenterology

Article Title: Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease

doi: 10.1186/s12876-022-02334-6

Figure Lengend Snippet: Baseline anthropometry, faecal calprotectin concentrations and urinary and plasma concentrations of iFABP

Article Snippet: Plasma and urinary iFABP concentrations were determined using the Quantikine anti-Human-iFABP (DFBP20) (R&D Systems Bio-Techne) ELISA kit according to the manufacturer’s instructions.

Techniques: Clinical Proteomics

Boxplots A plasma, B urinary iFABP concentrations in Controls and patients with Coeliac during GFD; C plasma, D urinary iFABP concentration in Controls and patients with Colitis and Crohn’s during exclusive enteral nutrition. Coeliac: coeliac disease, ND: newly diagnosed, Crohn’s: Crohn’s disease, Controls: healthy control, mo: month, GFD: gluten-free diet, EEN: exclusive enteral nutrition. Urinary iFABP measurements are expressed after urinary creatinine correction, a: p < 0.05 compared with Controls; b: p < 0.05 compared with ND Coeliac

Journal: BMC Gastroenterology

Article Title: Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Crohn’s disease

doi: 10.1186/s12876-022-02334-6

Figure Lengend Snippet: Boxplots A plasma, B urinary iFABP concentrations in Controls and patients with Coeliac during GFD; C plasma, D urinary iFABP concentration in Controls and patients with Colitis and Crohn’s during exclusive enteral nutrition. Coeliac: coeliac disease, ND: newly diagnosed, Crohn’s: Crohn’s disease, Controls: healthy control, mo: month, GFD: gluten-free diet, EEN: exclusive enteral nutrition. Urinary iFABP measurements are expressed after urinary creatinine correction, a: p < 0.05 compared with Controls; b: p < 0.05 compared with ND Coeliac

Article Snippet: Plasma and urinary iFABP concentrations were determined using the Quantikine anti-Human-iFABP (DFBP20) (R&D Systems Bio-Techne) ELISA kit according to the manufacturer’s instructions.

Techniques: Clinical Proteomics, Concentration Assay, Control